Rosiglitazone Metformin

For patients on doses of metformin hydrochloride between 1000 and 2000 mg/day, initiation of rosiglitazone/metformin requires individualization of therapy. 

Do not initiate therapy if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT more than 2.5 times upper limit of normal at start of therapy). Liver enzyme monitoring is recommended in all patients prior to initiation of therapy with rosiglitazone/metformin and periodically thereafter. 

Rosiglitazone (Avandia) Rosiglitazone/Metformin (Avandamet) Sitagliptin (Januvia) Sitagliptin/Metformin (Janumet)... 

Kahn SE et al Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl 3 Med 2006 355 2427. [PMID 17145742]... 

Table 2. Vascular serious adverse events during treatment with rosiglitazone, metformin or glibenclamide in the ADOPT-study population (for details see text and ref. 42).

Poulsen MK, Henriksen JE, Hother-Nielsen O, et al. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003 26(12) 3273-3279. 

Avandamet (Rosiglitazone/Metformin). Gl oSmithKhne UK. UK Summary of X oduct characteristics, June 2007. 

UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 837-853 Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 2427-2443... 

---